

Active Biotech Q1 2024 - Approching Naptumomab Topline Data in Lung Cancer

Redeye provides its view of Active Biotech's first quarter report of 2024.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Active Biotech Q1 2024 - Approching Naptumomab Topline Data in Lung Cancer